No 13S (2018)

Cover Page

Full Issue

PDF(Russian)
Articles
2017 Events (from open information sources)
Article E.
Abstract
January state Minister of Health Veronika Skvortsova announced the launch of pilot projects on risk sharing with the participation of four drugs in Moscow, the Moscow region and the Kaluga region at the Gaidar Forum. During 2017, these projects have not been launched. FAS made a statement л against these projects as it considered that no adequate legal mechanisms were developed to implement the pilot projects. FAS also believes that the risk-sharing system can not be used for drugs that lost the patent protection, have any registered analogues, are included in the VED list (one of the drugs included in the pilot project did not meet these requirements). • Russia FAS published a report on the results of the second stage of the comparative analysis of prices for drugs for the treatment of HIV, hepatitis B and C, as well as antibacterial and anti-tuberculosis drugs used to treat patients with multidrug-resistant tuberculosis. The registered marginal manufacturer prices for 95 items were higher in Russia than in some reference countries. The second stage results led to a drop in prices for 266 items, which was, among other things, the consequence and voluntary initiative of the companies. Earlier, the registration prices for 112 drugs were reduced as a result of the first stage of price monitoring, which affected the Seven Nosologies Program and ended in 2016.
REMEDIUM. 2018;(13S):8-15
views
Macroeconomic preconditions for the development of pharmaceutical market in the medium-term perspective
Trofimova E.O.
Abstract
In 2017, the Russian economy emerged from the recession, and it is expected to grow in the medium term. The risks for its growth are created by the foreign policy crisis, anti-Russian sanctions, energy price volatility. The projected low growth rates of household incomes will create restrictions for the growth of the commercial part of the pharmaceutical market. Healthcare is one of the priorities of the country's socioeconomic development for the new presidential term, which is fundamentally important for solving the country's demographic and socio-economic problems. In this situation, the most problematic areas of drug provision can expect an increase in funding out of the government sources. However, measures aimed at improving the economic efficiency of public procurements will be of no less importance for solving these tasks. a 15% increase in consolidated health care expenditures is planned in 2018, largely due to the electoral cycle and the need to implement the President's May decrees. According to the adopted budgets, the growth rate is planned at the level of forecast inflation in 2019-2020. At the same time, the health sector should receive higher funding as follows from the statements of the government, when working on a new three-year federal budget.
REMEDIUM. 2018;(13S):20-31
views
Demographic situation World market
Article E.
Abstract
According to the Rosstat's preliminary data, the resident population of Russia amounted to 146.9 mil. as of January 1, 2018 (Table 1). In January-December 2017, the population increased by 76.0 th. or by 0.05% (by 259.7 th. people, or 0.2% for the same period last year).
REMEDIUM. 2018;(13S):32-34
views
World market
Article E.
Abstract
According to the preliminary IQVIA1 data, the global drugs sales should be more than USD 1135 bil. (exclusive of discounts and bonuses) following the results of 2017. The average annual growth rates of sales are estimated at 6.2% in 2013-2017. In the following five years, drug spending is forecast to grow at 3-6% per year. The global pharmaceutical market will grow due to bringing innovative drugs to the markets of developed countries and increasing the consumption of drugs in developing countries.
REMEDIUM. 2018;(13S):35-39
views
The Russian pharmaceutical industry at year-end 2017
Trofimova E.O.
Abstract
In 2017, the Russian companies continued to expand their shares in the domestic market: the share of sales of domestic pharmaceutical drugs was about 62% in physical terms and 30% in value terms. The sales growth was mainly provided by the state purchases. The industry showed a high level of investment activity with widely used signing of the special investment contracts.
REMEDIUM. 2018;(13S):41-52
views
Pharmacy segment
Article E.
Abstract
According to IQVIA, the retail sales in physical terms declined by 1% in 2017 after growth observed in the previous year. The sales increased by 4.7% at wholesale and 3.5% at retail prices in national currency (Figure 1). Due to strengthening of the ruble and weakening of the dollar, the market dynamics in dollar terms was at a high level (19.5 and 18.2% respectively). In absolute terms, the market volume amounted to 4.5 bil. packs or RUB 698.6 bil. in wholesale and RUB 871.1 bil. in retail prices (USD 12.0 and 14.9 bil., respectively).
REMEDIUM. 2018;(13S):54-62
views
Budget segment (exclusive of subsidized drug coverage)
Article E.
Abstract
According to IQVIA13, the total budget segment14 exclusive of federal and regional subsidized drug coverage programs amounted to 748.6 mil. packs or RUB 186.1 bil. (USD 3.2 bil.) at wholesale prices in 2017 (Figure 1). In 2017, the budget purchases in physical and value terms increased by 20 %, in dollar terms by 35%. In the previous year, there was a negative dynamics.
REMEDIUM. 2018;(13S):63-71
views
ONLS/7 Nozologies Segment
Article E.
Abstract
According to IQVIA, the volume of total supplies under ONLS17 and 7 Nosology programs in contract prices amounted to RUB 114.51 bil. (USD 1.97 bil.) in 2017 (Figure 1). Compared to the previous year, the segment grew by 6.5% in the national currency and 26%. in dollar terms. In physical terms, the shipments decreased by 1% and amounted to 79.77 bil. packs.
REMEDIUM. 2018;(13S):72-84
views
Segment of regional reimbursement programs
Article E.
Abstract
According to the IQVIA database, the volume of purchases1 under the regional reimbursement programs (without mixed trades) amounted to 66.5 mil. packs totaling to RUB 55.7 bil., or USD 1.2 bil in 2017. As compared to the previous year, purchases increased by 31% in physical terms and by 28% in terms of national currency (by 47% in terms of dollars) (Figure 1).
REMEDIUM. 2018;(13S):85-88
views
Russian pharmaceutical market: results and forecasts
Article E.
Abstract
According to IQVIA, the Russian pharmaceutical market increased by 1.7% in physical terms, amounting to 5.4 bil. packs in 2017. In the national currency, the market grew at wholesale prices by 8.7% to RUB 1,070.8 bil., and by 7.2% to RUB 1,243.2 bil. at retail prices. The growth rate slightly decreased compared to the previous year. At the same time, the market in the dollar equivalent increased by about a quarter to USD 18.4 bil. at wholesale prices and USD 21.3 bil. at retail prices (Figure 1). In per capita terms18, drug consumption increased by 7% and amounted to RUB 8,469 (Figure 2).
REMEDIUM. 2018;(13S):89-102
views
Analysis of the FFP Tender Market in 2017
Article E.
Abstract
The results of the implementation of the import substitution program as one of the key strategic priorities of the country are particularly noticeable in the public procurement segment. The 2016 trend towards an increased consumption of drugs produced in the Russian Federation persisted in 2017. The drugs became more accessible for patients as a result of state support for import substitution.
REMEDIUM. 2018;(13S):103-113
views
Top drugs of the Russian pharmaceutical market in 2017
Article E.
Abstract
Every year Remedium publishes the traditional top 30 drug groups rating by sales in terms of value in 2017 (Table 1). Since the ATC classification is not the only classification system, the top drug groups ranking according to the EphMRA classification (European Association for Pharmaceutical Market Research, Table2) is presented for convenience.
REMEDIUM. 2018;(13S):114-156
views
Cerebrolysin® is currently enjoying a new lease on life
Prozherina J.
Abstract
The high prevalence of neurological diseases, primarily ischemic stroke and cognitive impairments, dictate the need for a rational choice of the most effective drugs. It was previously thought that vasoactive drugs are of the greatest importance for the recovery of brain functions, now the emphasis is shifted towards neuroprotective and neurotrophic agents. One such an example is Cerebrolysin® (EVER Neuro Pharma, Austria) resulting from extracting the peptide fraction of the young pigs brain [1]. This brand is well known to a wide range of Russian clinicians, primarily neurologists and psychiatrists [2]. However, even those health professionals who are already familiar with the drug should look at it again: Cerebrolysin® is currently enjoying a new lease on life.
REMEDIUM. 2018;(13S):157-162
views
Import substitution and localization results in Russia, 2017
Bespalov N.
Abstract
In 2017, the Russian pharmaceutical industry slowed down markedly in growth. 4.5 bil. drug packs were produced for a total of RUB 333.6 bil. in our country at the end of 2017 (at producers' prices, including VAT). At the same time, the dynamics of drug production in terms of rubles amounted to only 6.1%, which is four times lower than the indices recorded during the previous two years. The natural growth rate demonstrated a negative trend at the end of 2017 (-0,3 %).
REMEDIUM. 2018;(13S):162-168
views
Supplies of drugs produced in the EEU to Russia
Bespalov N.
Abstract
The economic integration processes in the post-Soviet space can only be welcomed. However, the formation of the Customs Union led to the abolition of customs control on the actual borders of the countries participating in the EEU, and thus deprived the pharmaceutical market of publicly available statistics on the transfer of drugs between our countries. Meanwhile, the turnover in this direction is quite high: only in 2017, the drugs produced in the EEU countries that were imported to Russia totaled to about RUB 8.4 bil. (at wholesale prices), moreover, the cash volume of such supplies shows a fairly confident positive dynamics.
REMEDIUM. 2018;(13S):169-173
views
Cursor: analytical Review of auctions for medicinal products the territory of Russia at year-end 2017
Article E.
Abstract
In 2017, after several years of a steady growth, the market for state purchases of medicinal products declined both in value terms and in terms of announced auctions. The volume of purchases in value terms (at the winner's price) fell by 7% from 366 to 340 bil. rubles. The number of announced auctions reduced by 8% (Tables 1, 2, Figures 1, 2). At the same time, the share of completed auctions slightly increased from 85.3 to 87.1% as compared to 2016 (Figure 3). The initial bidding price exceeded the winner's price by 32 bil. rubles in 2017, or 8.7%, which is slightly lower than the same indicator in 2016 - 10.1% (Table 2).
REMEDIUM. 2018;(13S):174-180
views
Overview of BAA pharmacy sales: 2017 results
Nechaeva J.
Abstract
The BAA pharmacy market has changed significantly over the past few years. First of all, the consumption pattern has changed. The most popular are the average price BAAs in such groups as vitamins, soothing, laxatives, sedative agents, medium-priced teas. But previously popular BAAs such as weight loss drugs, men's health drugs saw a significant drop in sales.
REMEDIUM. 2018;(13S):184-191
views
Review of cosmetics sales in pharmacies: 2017 results
Nechaeva J.
Abstract
Cosmetics became an integral part of the pharmacy range. Manufacturers of cosmetics position their products as unique, advertising its safety, effectiveness, and medicinal properties. And this position is justified, as the presence of a safety certificate and the marketing authorization clearance is a mandatory condition for the cosmetics to be placed on the pharmacy shelves.
REMEDIUM. 2018;(13S):192-198
views
Digitalization in the healthcare and the pharmaceutical industry quo vadis?
Lavrentieva A.
Abstract
Since 2007, PwC has been conducting a Digital IQ study that provides information on how companies in the medical and pharmaceutical industries benefit from technology and what role they assign to technology in the digital strategy transformation. The study involves the companies from all over the world. Recently, the tenth jubilee edition has been released, presenting the results of a survey of the heads of IT services and business units. In this article, we will present the main findings of the latest Digital IQ study.
REMEDIUM. 2018;(13S):202-209
views
Pharmaceutical advertising at-year end 2017
Article E.
Abstract
Remedium publishes an annual review of the pharmaceutical advertising segment in the Drugs and Biologically Active Additives (BAA) category at year-end 2017.
REMEDIUM. 2018;(13S):204-209
views
Main trends in the Moscow labor market in medicine and pharmaceutics in 2017
Ignatova M.
Abstract
After having analyzed 110 th. vacancies and more than 135 th. CVs in the medical and pharmaceutical industry specifically for Remedium Group in Moscow for the period from January 1, 2013 to March 15, 2018, the Research Service of HeadHunter revealed the main trends in this labor market.
REMEDIUM. 2018;(13S):210-218
views
GENERIUM: the territory of the future
Article E.
Abstract
GENERIUM JSC has confident standing in the biotechnological innovation segment, being the leading Russian manufacturer of genetic engineering drugs to treat hemophilia, tuberculosis and multiple sclerosis [1]. The pronounced social orientation of projects and high scientific potential allows the company to successfully solve the import substitution issues.
REMEDIUM. 2018;(13S):222-223
views
Evolution from import substitution to expansion into the foreign markets
Article E.
Abstract
The past year exploded with important news from Sotex. First, the purchase of the largest pharmaceutical complex Rafarma JSC by Protek Group. Then, reports on the successful entry into the EU market, the participation of the Russian manufacturer in the key industry events of the European pharmaceutical industry, and the announcement of large-scale international expansion plans. And at the same time, active operations on localization of foreign manufacture on the territory of Russia, competent alignment of the partner relations with the largest players of the world pharma. Our questions about the development strategy of the company were answered by Vadim Yatsuk, Director General, Sotex PharmFirm CJSC.
REMEDIUM. 2018;(13S):224-225
views
Vikram Punia: «Our key goal is to reduce dependence of the country on drug imports»
Article E.
Abstract
The saturation of the Russian market with modern domestic products, not inferior to imported analogues, is becoming especially topical upon the complex international relationships throughout the world. This task is successfully solved in Pharmasyntez, which consistently develops new nosological directions, fixing the most "sensitive issues" of the Russian pharmaceutical industry. We asked Vikram PUNIA, President of Pharmasyntez JSC, to share his vision of the company's strategy and talk about the results achieved.
REMEDIUM. 2018;(13S):226-228
views
Success formula of contour plus: affordability, quality and accuracy
Article E.
Abstract
Globally, an estimated 422 mil. adults are living with diabetes mellitus, according to the latest data from the World Health Organization (WHO). [1]. In Russia, the number of patients reached 4.3 mil. in 2016, and their number has increased by 2.3 mil. over the past 15 years [2]. Improving the quality of diagnosis [1] and self-monitoring of this disease is one of the key measures in the fight against diabetes. Therefore, glucometers and test strips remain the most important category among the pharmacy products.
REMEDIUM. 2018;(13S):229-229
views
Defeating Cancer: R-Pharm aligns itself with the world immunonocology and cellular therapy
Article E.
Abstract
R-Pharm is one of the largest Russian research-focused pharmaceutical companies that develops, manufactures and delivers drugs worldwide. Now the company is going through a new important stage of development.
REMEDIUM. 2018;(13S):230-231
views

Mailing Address

Address: 105064, Moscow, st. Vorontsovo Pole, 12, building 1

Email: redactor@remedium-journal.ru

Phone: +7(495) 917-48-86



Principal Contact

Sherstneva Elena Vladimirovna
EXECUTIVE SECRETARY
National research Institute of public health named after N. A. Semashko

105064, Vorontsovo Pole st., 12, Moscow


Email: redactor@remedium-journal.ru

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies